Packer, Milton
Article History
Received: 4 July 2023
Accepted: 28 July 2023
First Online: 2 August 2023
Declarations
:
: During the past three years, Dr. Packer reports personal fees for consulting from 89bio, Abbvie, Actavis, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Moderna, Novartis, Pharmacocosmos, Reata, Relypsa, SalamandraDr. Packer was the chair of the Executive Committee for the EMPEROR Trial Program, which evaluated the effect of empagliflozin in patients with heart failure and a reduced or preserved ejection fraction (EMPEROR-Reduced and EMPEROR-Preserved, respectively. This work is not related to any of the competing interests, described above.
: Not applicable. Not applicable.
: There is only one author who takes responsibility for the entire work.